Two major clinical trials are leading the charge.
Imagine giving your dog more time. Years, even decades, of extra tail wags, walks, and cuddles. For thousands of dogs in the United States, that future might already be taking shape in the form of a daily pill designed to slow aging.
Two major clinical trials are leading the charge. The first, called STAY, is led by the biotech company Loyal and involves giving a daily pill, LOY-002, to 1,300 dogs across more than 70 veterinary clinics.
The second, part of the Dog Aging Project and known as TRIAD, is testing various doses of rapamycin, an immunosuppressant, in roughly 850 dogs nationwide.
